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Abstract
Attention deficit hyperactivity disorder (ADHD) is a
neurocognitive behavioral developmental disorder
most commonly seen in childhood and adolescence,
which often extends to the adult years. Relative to a
decade ago, there has been extensive research into
understanding the factors underlying ADHD, leading
to far more treatment options available for both
adolescents and adults with this disorder. Novel
stimulant formulations have made it possible to tailor
treatment to the duration of efficacy required by
patients, and to help mitigate the potential for abuse,
misuse and diversion. Several new non-stimulant
options have also emerged in the past few years.
Among these, cognitive behavioral interventions have
proven popular in the treatment of adult ADHD,
especially within the adult population who cannot or
will not use medications, along with the many
medication-treated patients who continue to show
residual disability.
Introduction
Attention deficit hyperactivity disorder (ADHD) is a
neurobehavioral disorder that is defined by persistent
and maladaptive symptoms of hyperactivity/impulsivity
and inattention [1] (please see Table 1 for diagnostic
criteria). People with ADHD often have serious impair-
ments in academic, social and interpersonal functioning.
ADHD is also associated with several comorbid condi-
tions and disorders such as mood disorders, disruptive
behavior disorders and learning disabilities. This review
will review current conceptualizations of the causes of
ADHD and advances in treatment, including discussions
of stimulant and non-stimulant medication and cogni-
tive behavioral therapy (CBT).
Understanding ADHD
T h eA D H Dp r e v a l e n c ew a so n c ee s t i m a t e dt ob e3t o
5% of school-age children [1], but more recent studies
place the figure closer to 7 to 8% of school-age children
[2] and 4 to 5% of adults [3]. Prevalence clearly varies,
with risk factors including age, male gender, chronic
health problems, family dysfunction, low socioeconomic
status, presence of a developmental impairment and
urban living [4]. The disorder is found in all countries
surveyed, with rates similar to, if not higher than, those
found in North America [5,6]. Differences across ethnic
groups within North America are sometimes found, but
seem to be more a function of social class than ethnicity
[7]. Although diagnosed as a categorical disorder,
ADHD may actually represent the extreme end of a nor-
mal continuum for the traits of attention, inhibition and
the regulation of motor activity [8].
Current advances in cognitive neuroscience, neuroi-
maging, and behavioral and molecular genetics have
provided evidence that ADHD is a complex neurobiolo-
gical disorder. Many regions of the brain and several
neurotransmitters have been implicated in ADHD. Bio-
logically, the neurotransmitter dopamine has received
considerable attention as being relevant to understand-
ing ADHD. Neurologically, the prefrontal cortex seems
to be relevant to understanding ADHD. The prefrontal
cortex has a high requirement for dopamine, and plays
a role in cognitive functions such as executive functions.
The prefrontal cortex has many reciprocal connections
with other brain regions, including the striatum (caudate
nucleus, putamen), cerebellum and parietal cortex.
Research has indicated that some of these brain regions
are slightly smaller or have decreased activation in peo-
ple with ADHD.
Comorbid conditions
Pediatric ADHD commonly co-occurs with multiple
psychiatric disorders including mood, anxiety and dis-
ruptive behavioral disorders [9,10]. Likewise, adult
ADHD is also associated with diagnoses of comorbid
mood, anxiety and substance-use disorder [11-17].
Comorbidity rates in adult ADHD do not differ as a
function of gender [18]. ADHD in adults is not always
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and some data suggest that ‘uncomplicated’ ADHD
exists in about 20 to 25% of adults with ADHD [13].
Current research
Research on ADH) has been published at an exponential
rate during the past 30 years [19]. Within the past 3
years (2008 onwards), theories about the etiology of
ADHD and therapies for it have evolved concurrently
[20-23]. Psychopharmacological agents affecting cate-
cholaminergic and a-2-adrenergic transmission continue
to figure prominently in ADHD treatment [24,25]. Over
the past 3 years, however, more attention has been paid
to prescribing patterns [26-28], matching medication
with patient characteristics [29], and factors that pro-
mote treatment adherence in pediatric [30-35] and
young adult populations [36]. In the following section,
current treatment options for both adults and children
with ADHD will be discussed.
ADHD treatments
There are both pharmacological and non-pharmacologi-
cal treatments for ADHD for both children and adults.
Pharmacological approaches to treatment are the most
common, and typically consist of stimulant medication,
such as methylphenidate, dexmethylphenidate, mixed
amphetamine salts and lisdexamfetamine dimesylate
(LDX). However, non-stimulants such as atomoxetine,
clonidine and guanfacine have also been found to be
efficacious in treating ADHD. In addition to medication,
there are also non-pharmacological treatments. Many of
the drugs discussed in this section are currently licensed
for use in North America, but not in other countries.
Treatment for children with ADHD includes parent
and teacher training in effective behavior-management
techniques aimed at reducing the problem behaviors
associated with ADHD. CBT is a skill-based approach
commonly used for adultsw i t hA D H Da n dt h e r ea r e
some preliminary data showing its efficacy.
Table 1 DSM-IV
a criteria for attention deficit hyperactivity disorder
A. Either 1 or 2
1. Six (or more) of the following symptoms of inattention have persisted for at least 6 months, to a degree that is maladaptive and inconsistent with
developmental level:
a. Often fails to give close attention to details, or makes careless mistakes in schoolwork, work or other activities
b. Often has difficulty sustaining attention in tasks or play activities
c. Often does not seem to listen when spoken to directly
d. Often does not follow through on instructions, and fails to finish schoolwork, chores or workplace duties (not due to oppositional behavior
or failure to understand instructions)
e. Often has difficulty organizing tasks and activities
f. Often avoids, dislikes or is reluctant to engage in tasks that require sustained mental effort (such as schoolwork or homework)
g. Often loses things necessary for tasks or activities (for example, toys, school assignments, pencils, books or tools)
h. Is often easily distracted by extraneous stimuli
i. Is often forgetful in daily activities
2. Six (or more) of the following symptoms of hyperactivity/impulsivity have persisted for at least 6 months, to a degree that is maladaptive and
inconsistent with developmental level:
a. Often fidgets with hands or feet or squirms in seat
b. Often leaves seat in classroom or in other situations in which remaining seated is expected
c. Often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, may be limited to subjective feelings
of restlessness)
d. Often has difficulty playing or engaging in leisure activities quietly
e. Is often ‘on the go’ or often acts as if ‘driven by a motor’
f. Often talks excessively
g. Often blurts out answers before questions have been completed
h. Often has difficulty awaiting turn
i. Often interrupts or intrudes on others (for example, butts into conversations or games)
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before 7 years of age
C. Some impairment from the symptoms is present in two or more settings (for example, at school/work or at home)
D. There must be clear evidence of clinically significant impairment in social, academic or occupational functioning
E. The symptoms do not occur exclusively during the course of a pervasive developmental disorder, schizophrenia or other psychotic disorder, and
are not better accounted for by another mental disorder (or example,, mood disorder, anxiety disorder, dissociative disorder or personality disorder)
aDiagnostic and Statistical Manual of Mental Disorders, Fourth edition
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For most patients with ADHD, stimulants remain the
first choice for medication management, as meta-ana-
lyses of existing research have shown that they are more
efficacious than non-stimulant medications [37]. Various
delivery mechanisms exist. Physicians may choose from
a number of delivery mechanisms for these stimulants
(liquid, sprinkle, tablet, capsule or patch); from active
isomer, mixtures of active and less active isomers, or
pro-drug; from and immediate-release, intermediate-
release or extended-release formulations [38]. For both
the methylphenidate and amphetamine families, there
are arrays of choices, which enable practitioners to bet-
ter tailor the duration of medication efficacy throughout
the day to the needs of the individual (please see Table
2 for descriptions of stimulant options).
Research has continued to suggest that osmotic-
release oral system (OROS) methylphenidate lessens
ADHD symptoms throughout the day and has greater
adherence, thought to be associated with the conveni-
ence of once-daily dosing [39-41]. Dexmethylphenidate
extended-release (XR) and transdermal methylphenidate
also offer this benefit. Dexmethylphenidate comes in
capsules that can be opened and mixed with food, and
has the earliest onset of efficacy of the long-acting pre-
parations [42,43]. Transdermal methylphenidate
bypasses the oral route entirely, and in short-term stu-
dies is associated with efficacy throughout the day, with
improved family quality of life, and when carefully
titrated, little effect on sleep [44-46]. Greater absorption
of medication occurs when the patch is applied to the
buttocks rather than to the subscapular area [47].
Comorbid anxiety was not found to affect stimulant
efficacy in a recent study [48], and some studies suggest
that treatment with stimulants can help to lessen the
likelihood of other psychiatric comorbidities during ado-
lescence [49], including cigarette use and substance
abuse [50]. However, meta-analyses of stimulants and
other ADHD medications in the treatment of ADHD
comorbid with tic disorders concluded that suprathera-
peutic doses of dextroamphetamine should be avoided
in this population. These studies also indicated that
methylphenidate gave the best control for ADHD and
that a-2-agonists produced the best improvement in
both tics and ADHD [51,52].
The commonest side-effects of stimulants (decreased
appetite, trouble with sleep onset) have also continued
to receive recent research interest. Some research sug-
gests that it is difficult to predict which children with
ADHD will have adverse effects, based upon demo-
graphic and clinical characteristics [53]. Although rare,
serious cardiovascular side-effects have been identified
with stimulant use [54]; however, the common effects
on blood pressure, heart rate and exercise parameters
are usually of no clinical significance [55-57]. Consensus
has been reached in the USA, Canada and Europe that
routine electrocardiography screening and/or cardiology
investigations are needed before starting stimulant use
only in those with a positive family or personal cardiac
history [58,59]. Likewise, no cytogenetic side-effects
from stimulant use have been reported [60,61]. How-
ever, a recent review article has shown that treatment
with stimulants in childhood modestly reduced expected
height and weight [62]. These effects were dose-depen-
dent and attenuated over time. The general consensus
on cardiovascular side-effects at this point is that the
short/medium term side-effects are usually of no clinical
significance, but the long-term potential side-effects are
less certain [63].
Within the past 3 years, concerns have continued to
rise regarding the abuse of stimulants and/or drug diver-
sion [64-66]. Some have suggested that in ADHD
patients with conduct disorder or comorbid substance
abuse, psychostimulants should be used with caution
[67]. Long-acting stimulants are less prone to diversion,
probably because extraction of active drug is more diffi-
cult, and for some, the delivery of drug to the brain is
slower. The new stimulant pro-drug LDX offers some
protection from these problems. LDX requires gut meta-
bolism to reach its active form, and hence lessens the
likelihood of abuse and overdose. The efficacy and side-
effects of LDX are similar to the other long-acting sti-
mulant preparations [68-72].
In summary, stimulant medication is often the first
choice for medication management of ADHD. Research
has shown that stimulant medication is an effective
treatment for many of the symptoms associated with
ADHD. However, there are some concerns about diver-
sion of these medications for misuse and abuse, and
some rare but serious cardiovascular side-effects can
occur with the use of stimulant medication. In addition
to stimulant medication, some non-stimulant medica-
tion has been shown to be efficacious for the treatment
of ADHD (Table 2).
Non-stimulants
Some children may not respond to stimulant medica-
tions, or may not be able to tolerate the stimulant medi-
cations due to side-effects (for example,, loss of
appetite). Thus, several non-stimulant medications are
also used for ADHD pharmacotherapy. Modafinil [73]
and reboxetine [74,75] have both shown some promise
in the treatment of ADHD. Drugs approved by the US
Food and Drug Administration (FDA) for the treatment
of ADHD include the selective norepinephrine reuptake
inhibitor (SNRI), atomoxetine, a long-acting form of
guanfacine, and a long-acting form of clonidine (Table
2). Clonidine and guanfacine have also been approved
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Page 3 of 12Table 2 Current pharmacological treatments approved for attention deficit hyperactivity disorder (ADHD)
Class Generic name, formulation
and brand name
Daily dosage Duration Mechanism of action Common Side-effects
STIMULANTS
Methylphenidate Immediate-release/short-acting
(Ritalin, Methylin, Desoxyn)
Initial 5-18 mg; increase as needed until beneficial
effects peak or unacceptable side effects develop
Two to three times daily; can titrate as needed as long
as beneficial effects are greater than side effects
3t o6
hours
Blocks reuptake of D,
N
Release of D from
storage vesicles
Appetite suppression, delay of sleep onset,
abdominal pain, headache, rebound irritability,
tics (motor, vocal), jitteriness
Intermediate-acting (Metadate
ER, Metadate CD, Methyllin ER,
Ritalin LA, Ritalin SR)
One to two times daily 3 to 8
hours
Same Same
Extended release/long-acting
(Concerta, Daytrana Patch)
Once daily (Patch left on for 9 hrs) 8 to 12
hours
Same Same
Dexmethylphenidate Short-acting (Focalin) Two to three times daily; initial half that of IR MPH 4 to 5
hours
Same Same
Extended-release/long-acting
(Focalin XR)
Once daily 8 to 12
hours
Same Same
Amphetamines Immediate-release/short-acting
(Dexedrine, DextroStat, Adderall)
Initial dose half IR MPH; two to three times daily 4 to 6
hours
Release of D newly
synthesized D; blocks
reuptake of D, N
Same
Intermediate-acting (Dexedrine
spansule)
One to two times daily 6 to 10
hours
Same Same
Extended-release/long-acting
(Adderall-XR)
Once daily 8 to 12
hours
Same Same
Prodrug
Amphetamines
Lisdexamfetamine (Vyvanse) Initial 4 × IR MPH once daily 8 to 12
hours
Same Same
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2Table 2 Current pharmacological treatments approved for attention deficit hyperactivity disorder (ADHD) (Continued)
NON - STIMULANTS
NRI Atomoxetine (Strattera) Initial 0.5 mg/Kg; Increase to 1.2-1.8 mg/Kg one to 2
times a day
18 to 24
hours
Blocks N reuptake at
synapse
Sedation, GI irritability, palpitations, sweating,
increased suicidal thoughts
ALPHA2 AGONISTS
Clonidine IR Clonidine (Catapres) Initial dose 0.05-0.1 mg at night; titrate to max 0.4 mg/
per day
3t o6
hours
Arousal at locus
ceruleus by N
inhibition
Sedation, Low blood pressure, rebound
hypertension
ER Clonidine (Kapvay) Initial 0.1 mg qhs; titrate to max 0.4 mg qhs; once daily 12 to 24
hours
Same Same
Clonidine patch (catapres TDS) Initial TTS-1 up to TTS-3 1 to 5
days
Same Same
Guanfacine IR Guanfacine (Tenex) Initial 1 mg daily; titrate as needed up to 4 mg MDD;
twice daily
12 to 24
hours
Same Same
ER guanfacine (Intuniv) Initial 1 mg; up to 4 mg; once daily ~24
hours
Same Same
ANTIDEPRESSANTS
NDRI Buproprion Initial: lesser of 3 mg/Kg/d or 150 mg; Maximum: Lesser
of 6 mg/Kg/d or 450 mg; No singled does greater than
150 mg; 2 to 3 times a day
8t o1 2
hours
N and D reuptake
inhibition
Insomnia, decreased appetite, irritability,
anticholinergic (dry mouth, GI etc.), decreased
seizure threshold
IR (Wellbutrin) Same Same
ER (Wellbutrin SR) Twice daily 12 to 24
hours
Same Same
(Wellbutrin XL) Once daily 24 hours Same Same
SNRI’s (Tricyclics) Imipramine (Tofranil) Initial: 1 mg/Kg/d; Maximum: Lesser of 4 mg/Kg/d or
200 mg; 1 to 2 times per day; obtain baseline EKG;
Monitor serum levels
12 to 24
hours
N and Serotonin
reuptake blockade
Sedation, Cardiac increase heart rate,
arrhythmias, anticholinergic (dry mouth, GI,
etc.), blurry vision
D = Dopamine, N = Norepinephrine, S = Serotonin, IR = Immediate Release, MPH = Methylphenidate, mg/kg = milligrams/kilogram, qhs = before bed
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2by the FDA for coadministration with stimulant
medication.
Several reviews on the use of atomoxetine have been
published recently [76,77], and studies in populations
around the world have continued to confirm its efficacy
[78-81], including for children with oppositional defiant
disorder [82] or those who have received previous sti-
mulant therapy [83]. When atomoxetine is administered
once daily, some evidence suggests that morning dosing
may be more efficacious, but evening dosing may be
more tolerable [84]. In adolescents, doses in the higher
ranges have been associated with greater long-term effi-
cacy [85]. Because atomoxetine has been rarely asso-
ciated with acute suicidality [86], it has been given a
‘black box’ warning. As with stimulant treatment, ato-
moxetine rarely completely normalizes behavior [87],
but symptom improvement is often reflected in gains in
social and behavioral function [88].
The a-2-adrenergic agonists clonidine and guanfacine
have long been known to be of some assistance in treat-
ing ADHD [89]. Recently, once-daily extended-release
guanfacine has proven effective in both short-term
[90,91] and long-term studies [92,93]. Sedation is a com-
mon side-effect, which diminishes over time [94].
Response to single-agent treatment for ADHD often
falls short of full remission. Recent studies have shown
that adding clonidine to methylphenidate [95],
extended-release guanfacine to stimulants [96], or
OROS methylphenidate to atomoxetine [97] improved
residual ADHD symptoms and was well tolerated. The
FDA recently approved a long-acting form of clonidine
to be used in monotherapy or as an adjunctive therapy
to stimulant medications.
Treatment of ADHD can result in alleviation of
comorbid depression, anxiety, oppositional defiant disor-
der and/or aggression [98]. However, when this is not
the case, polypharmacy targeting each condition may
have added benefit without unacceptable side-effects.
Examples include use of atomoxetine or methylpheni-
date in children being treated for bipolar spectrum dis-
orders [99,100] or borderline personality disorder [101],
and atypical antipsychotics [102] or valproic acid pre-
parations [103] for children with ADHD and aggression
or bipolar disorder. For patients with autistic spectrum
disorder, optimal results may require stimulants, SNRIs,
antipsychotics and a-2-agonists [104].
A number of reports have been published about the
use of alternative and complementary medicines in the
treatment of ADHD. In a small study, traditional Chi-
nese medicines were found to compare favorably with
methylphenidate [105]. Positive results were claimed for
gingko biloba [106], but this failed in head-to-head com-
parison with methylphenidate [107]. Short-chain fatty
acids [108] and omega-3/omega-6 fatty acids [109] have
not been found to be efficacious. A meta-analysis of
neurofeedback treatment studies reported encouraging
results that suggested the approach would be more
effective for inattention and impulsivity than for hyper-
activity [110]. Cognitive training paradigms [111] have
also been forwarded as a potential treatment stratagem,
although these data require further research before any
meaningful conclusions can be reached. At this point,
the consensus for most alternative and complementary
therapies is that these therapies are best used as a com-
plement to ongoing pharmacotherapy rather than as an
alternative.
Adult ADHD treatment
The need for treatment in adults with ADHD has been
debated in the past, with reports of suboptimal response,
diversion and abuse. There is a growing body of
research on the treatment, and recent years have seen
the creation of evidence-based guidelines [112]. Meta-
analysis of pharmacological agents for managing adult
ADHD have shown that stimulant medications are more
effective than non-stimulant medications. This is in line
with pediatric ADHD, for which stimulants are also gen-
erally considered the front-line approach [113]. Also
similar to pediatric ADHD, stimulants are generally con-
sidered the front-line approach for managing adult
ADHD. Unlike pediatric ADHD, all the agents approved
b yt h eF D Af o rt r e a t i n ga d u l tA D H Da r el o n g - a c t i n g .
Interestingly, some research suggests that only 49% of
adults are prescribed long-acting agents [114]. The pro-
portion of adults on long-acting agents is considerably
lower than that for children.
Non-stimulant options are also similar to pediatric
ADHD options, although bupropion and modafinil are
used more often in adults than in children with ADHD.
However, the only non-stimulant with FDA approval for
adults with ADHD is atomoxetine.
The potential for diversion and misuse may be greater
in adults than in children, as parents might control the
medications for the latter. Stimulant misuse seems to be
more common in those with comorbid alcohol-, drug-
and cigarette-related problems, and those with higher
levels of ADHD symptoms [115]. In addition, long-act-
ing stimulants are less likely to be misused or diverted
than short-acting stimulants.
In pediatric ADHD, a combined treatment approach
generally consists of pharmacotherapy and some form of
psychosocial intervention, generally consisting of train-
ing parents in behavioral management, consultation
with teachers/school personnel and individual work with
the child [116]. For example, behavioral parent training
(BPT) programs seem to be effective for children with
disruptive behaviors, irrespective of co-occurring atten-
tional/hyperactive difficulties. BPT techniques generally
consist of training parents in general operant
Antshel et al. BMC Medicine 2011, 9:72
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of reinforcement or punishment in response to appro-
priate/inappropriate behaviors. Reinforcement proce-
dures have typically relied on praise, privileges or
tokens, whereas punishment methods have usually been
loss of positive attention, privileges or tokens, or formal
‘time out’ from reinforcement.
In adults, a combined treatment approach similarly
typically consists of pharmacotherapy and psychosocial
intervention. However, unlike pediatric ADHD, there is
some evidence that CBT interventions are efficacious
(please see Table 3 for list of common non-pharmacolo-
gical interventions for managing ADHD).
CBT joins together cognitive and behavioral therapies,
and gained popularity in the late 1960s as a treatment
approach. Cognitive therapists believe that how a person
interprets an event is more important than the actual
event itself. Therefore, treatment focuses more on cog-
nitions than on overt behaviors; reducing dysfunctional
thoughts helps to improve adjustment [117]. Behavioral
models emphasize the role of basic learning principles
(operant conditioning, classic conditioning, observational
learning) in developing and maintaining behavior, both
adaptive and maladaptive. Rather than focusing on cog-
nitions, behavioral therapy spotlights the stimuli and
contingencies that maintain maladaptive behaviors.
Treatments that are cognitive-behavioral in nature
include both cognitive and behavioral procedures and
have at their core three fundamental beliefs [118]: 1)
cognitive activity affects behavior; 2) cognitive activity
can be monitored and modified and 3) behavioral
change can be produced by cognitive change.
Safren et al. developed a CBT program for adults with
ADHD as a supplement to their medication treatment
[119]. A recently published study suggests that, when
compared with adults with ADHD who received relaxa-
tion training and educational support, adults with
ADHD who received 12 sessions of CBT had lower self-
reported ADHD symptoms and greater functional
improvements as rated by a blinded assessor [119].
There were more treatment responders in the CBT
group (53%) relative to the relaxation training and edu-
cational support group (23%), and gains were main-
tained over periods of 6 and 12 months [119].
Bramham et al. also developed a group CBT workshop
program [120]. Using three 1-day workshops held
monthly, six sessions were included in the program. The
results suggested that, relative to the controls, adults
with ADHD who participated in the workshop increased
their knowledge of ADHD. However, less optimistically,
one-third of participants dropped out during the course
of the CBT workshop. Furthermore, both groups
reported less depression and anxiety. Both groups also
had improved self-esteem at the end of the study, but
the intervention group reported a greater improvement
in self-esteem [120]. Others have also recently developed
group interventions relying on CBT strategies [121].
In sum, CBT seems to be a promising treatment
approach to complement pharmacotherapy. At this
point, there is limited evidence that CBT is efficacious
on its own. However, when added to pharmacotherapy,
emerging evidence suggests CBT improves treatment
outcomes compared with medications alone.
Challenges of treating ADHD
There are several challenges associated with the treat-
ment of people with ADHD. The first challenge is
related to the clinical complexity of the cases them-
selves; the vast majority of people with ADHD, both
child and adult, have a comorbid psychiatric disorder
[122-125]. Thus, even relatively successful treatment of
the ADHD symptoms may be associated with only mod-
est functional improvements in the real world.
I nt h ep r e s e n c eo fs i g n i f i c a nt comorbidity, complex
combined treatments may be required, and the results
may be frustrating. Diligent attempts to clarify the co-
occurring conditions and related features (for example,
poor social skills, low academic abilities become essen-
tial in cases resistant to treatment. Although most peo-
ple with ADHD will respond favorably to
pharmacological interventions [126], optimal functioning
may not be attained. Even in non-comorbid ADHD
cases, optimal functioning occurs in only roughly one in
four children with ADHD [127,128]. Most patients show
residual disabilities in several areas, including executive
functioning, deficient emotional self-regulation, and
‘real-world’ functioning in school or employment, or in
maintaining relationships. Some have suggested that
ADHD is a disorder of performance, not knowledge
[129]. Thus, despite reduced ADHD symptoms and
knowing how best to manage their affairs, residual
impulsivity often continues to negatively affect function-
ing. For this reason, establishing reasonable expectations
with patients and parents may be crucial for the success
and continuity of the treatment. Likewise, medications
may improve some but not all aspects of cognitive func-
tioning, and even when both symptoms and cognitive
function are improved, the two are not necessarily cor-
related [130].
A second challenge in treating ADHD is related to the
methods of treatment, and the optimization of the risk:
benefit ratio. Optimization of the treatment response
often requires careful adjustments in doses and particu-
lar distributions of the doses during the day to maxi-
mize the effect of medications at the point of
performance. Combined pharmacotherapy (for example,,
antidepressant plus stimulant for ADHD and comorbid
depression) is often needed for patients with comorbid
disorders, and is sometimes indicated when ADHD is
Antshel et al. BMC Medicine 2011, 9:72
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ments are often useful, but these should be targeted to
patients based on a needs assessment.
Possibly as a function of the disorder itself, non-adher-
ence to treatment regimens is high in ADHD [131]. In
addition to the disorganization inherent in the disorder,
other contributors to poor treatment adherence may be
denial, externalization of the problem and medication
side-effects [131]. Little is known about predictors of
long-term adherence, so more work is needed to
improve this crucial component of treatment efficacy.
In sum, despite considerable advances in our under-
standing and treating ADHD, the disorder remains diffi-
cult to manage. Poor treatment adherence and
psychiatric comorbidity clearly complicate treatment
and negatively affect outcomes.
Conclusions
Cognitive neuroscience has permitted a greater under-
standing of ADHD. Recent research and novel drug
developments have provided new treatment options for
adolescents and adults with ADHD. New stimulant for-
mulations have made it possible to tailor treatment to
the duration of efficacy required by patients and to help
mitigate the potential for abuse, misuse and diversion.
Although they tend to be less efficacious than stimu-
lants, new non-stimulant options also allow for extended
duration of treatment without the adverse consequences
associated with stimulant therapy. Progress in non-med-
ical therapies now provides several options for patients
who cannot or will not use medications, and for the
many medication-treated patients who continue to show
residual disability.
Looking toward the future, research will need to
address several unmet needs. Many treated people with
ADHD continue to have problems with executive func-
tioning and deficient emotional self-regulation. These
problems persist in many patients even when the core
ADHD symptoms (as outlined in the Diagnostic and
Statistical Manual of Mental Disorders, Fourth edition
(DSM-IV)) are effectively treated. Future treatment
development should aim at developing both psychoso-
cial and medical treatments for these areas of difficulty.
Future treatment research should also work to define
and achieve optimal treatment outcomes for people with
ADHD. Although current treatments are effective for
achieving substantial symptom reduction in most
patients, more work is needed to achieve full symptom
reduction, and to reduce the burden of ADHD-asso-
ciated disabilities.
There are also diagnostic challenges for clinicians that
could be addressed by future research. ADHD symp-
toms, especially hyperactive-impulsive symptoms, tend
to decline through adolescence into adulthood, so that
Table 3 Non-pharmacological treatments for attention deficity hyperactivity disorder (ADHD)
Name Description
Parent training in behavior
management
A training intervention is to gather a detailed accounting of behavioral problems including when and in what
situations misbehaviors occur. It is also useful to record how parents and other adults react to the behaviors, and
what subsequent interactions take place as a result of those reactions. In sum, what are the social contingencies
that might be cueing, exacerbating or sustaining inappropriate behavior, if any? What disciplinary methods are
used in the home now and in the past, and what formalized help have parents sought and obtained for managing
the problems? Both parents need to be involved if both have contact with the child. At the very least, the non-
attending parent must be supportive of the one attending training if the transfer of skills from the group to the
home setting is to be enhanced. If others regularly care for the child, they may also be involved in the training, so
that the child experiences consistency across the routine caregivers in his life.
School interventions Often include alterations to the curriculum and workload to better mesh with the limited attention, persistence
and disorganization of the child with ADHD; special educational services (’push-in’ or mainstreaming assistance to
regular teachers; ‘pull-out’ services to focus on more individualized child training, self-contained classes); increases
in sources of positive reinforcement for work productivity; occasional use of immediate and systematic negative
consequences for disruptive or inappropriate behavior; implementation of a daily school behavior report card (the
ratings on which are linked to a home token economy), peer-tutoring or other innovative approaches to using
peer influence to achieve classroom goals; and more communication with parents. In short, greater accountability
of the child to teachers and others, including more immediate, frequent and salient feedback for performance, and
increased structuring of the classroom environment and teaching materials have all been shown to benefit the
child with ADHD in school.
Cognitive behavioral therapy The emphasis on the process of restructuring or modifying an individual’s thoughts to create behavioral effects is
what differentiates CBT therapists from behavioral therapists. Aspects of CBT that differentiate the treatment from
other therapeutic orientations such as psychodynamic therapy and interpersonal therapy include the following.
￿ Use of homework and outside-of-session activities.
￿ The CBT therapist is more active and directs session activity.
￿ CBT focus is clearly on the future.
￿ The CBT therapist explicitly teaches skills for coping with symptoms.
￿ The CBT therapist focuses on cognitive experiences (especially dysfunctional thoughts and beliefs).
￿ The therapist provides explicit information to the patient about the treatment, the disorder and its symptoms.
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Page 8 of 12the adult presentation of ADHD differs somewhat from
the childhood presentation. Helping clinicians under-
stand these differences, and how such differences should
affect the application of diagnostic criteria requires
more work.
Ideally, medical and psychological treatments should
be tailored to the underlying pathophysiology of the
patient. Theoretically, this should be possible by using
t h es c i e n t i f i cl i t e r a t u r eo nt h en e u r o b i o l o g yo fA D H D
with treatment outcome studies, as it is possible that
patients with specific brain-imaging abnormalities or
genetic variants would have different responses to treat-
ments. To date, most of this work has been done in the
area of pharmacogenetics which, although promising,
cannot yet guide treatment choices [132-134]
In summary, although the science of ADHD and its
application to diagnosis and treatment have made great
strides, more work is needed to improve the lives of
patients and families affected by the disorder.
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